<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03546231</url>
  </required_header>
  <id_info>
    <org_study_id>PI2017_843_0027</org_study_id>
    <nct_id>NCT03546231</nct_id>
  </id_info>
  <brief_title>Characteristics and Prognosis of Moderate or Severe Tricuspid Regurgitation</brief_title>
  <acronym>EPIT</acronym>
  <official_title>Clinical and Echocardiographic Characteristics and Prognosis of trIcuspid regurgiTation (EPIT): Prospective and Retrospective Follow-up of a Cohort of Patients With Moderate or Severe Tricuspid Regurgitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire, Amiens</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire, Amiens</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tricuspid valve : its evaluation is relatively difficult in echocardiography and the&#xD;
      management of tricuspid valve diseases remains poorly codified.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The tricuspid valve is often called the &quot;forgotten valve&quot; because its evaluation is&#xD;
      relatively difficult in echocardiography and the management of tricuspid valve diseases&#xD;
      remains poorly codified. In developed countries, TR is mainly functional, related to a&#xD;
      remodeling of the right cavities in response to an increase in the load conditions. This&#xD;
      remodeling induces a dilation of the tricuspid ring and / or a &quot;tenting&quot; of the tricuspid&#xD;
      leaflets. Once TR is present, a vicious circle settles because TR increases right ventricle&#xD;
      dilation. Transthoracic echocardiography is the key examination allowing noninvasive,&#xD;
      quantification and assessment of hemodynamic repercussions of TR.&#xD;
&#xD;
      TR remains asymptomatic for a long time, often diagnosed with a significant delay at the&#xD;
      stage of advanced right heart failure. At this stage, the surgical risk is important, at&#xD;
      least more important than for left heart valve diseases and it is therefore essential to&#xD;
      define the right time for proposing valvular surgery to patients. Indeed, TR is an&#xD;
      independent factor of mortality and only surgical treatment improves the prognosis.&#xD;
&#xD;
      Current guidelines remain vague given the low number of prognostic studies and of their&#xD;
      contradictory results often influenced by the significant comorbidities of patients, the&#xD;
      presence of pulmonary hypertension or left heart valve disease. Only a minority of patients&#xD;
      (&lt;1%) is referred to surgery because operative mortality is often judged unacceptable in&#xD;
      elderly patients or in cases of advanced right ventricular dysfunction.&#xD;
&#xD;
      The constitution of a prospective and retrospective cohort will improve the state of&#xD;
      knowledge on etiologies, natural history, prognosis and management of patients with moderate&#xD;
      or severe TR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2, 2018</start_date>
  <completion_date type="Anticipated">July 2025</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 Years</time_frame>
    <description>It corresponds to the delay between the diagnostic and the date of death.</description>
  </primary_outcome>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Tricuspid Valve Disease</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with moderate or severe tricuspid regurgitation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 ans&#xD;
&#xD;
          -  inclusion criteria: moderate or severe tricuspid regurgitation&#xD;
&#xD;
          -  exclusion criteria: Refusal to participate/ prior surgery of the tricuspid valve&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christophe TRIBOUILLOY, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU AMIENS-PICARDIE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christophe TRIBOUILLOY, Pr</last_name>
    <phone>03 22 45 58 85</phone>
    <email>Tribouilloy.Christophe@chu-amiens.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens-Picardie</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>CHRISTOPHE TRIBOUILLOY</last_name>
      <phone>03-22-08-72-51</phone>
      <email>Tribouilloy.Christophe@chu-amiens.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2018</study_first_posted>
  <last_update_submitted>July 7, 2021</last_update_submitted>
  <last_update_submitted_qc>July 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tricuspid regurgitation</keyword>
  <keyword>tricuspid valve</keyword>
  <keyword>surgery</keyword>
  <keyword>outcome</keyword>
  <keyword>prognosis</keyword>
  <keyword>mortality</keyword>
  <keyword>right ventricle</keyword>
  <keyword>asymptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tricuspid Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

